The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic
The Global Human Growth Hormone Market size is expected to reach $7.1 billion by 2025, rising at a market growth of 8.3% CAGR during the forecast period. Human growth hormone (HGH), also referred to as somatotropin, is a peptide hormone that stimulates growth, helps in cell reproduction as well as regeneration in humans. It is therefore important in human development. Growth hormone (GH) deficiency in humans is triggered when the pituitary gland does not synthesize enough HGH concentration. This deficiency in humans is treated by subcutaneous injection of recombinant human growth hormone. In the pituitary gland, the human body naturally produces growth hormones. The growth hormone is processed and secreted by somatotropic cells present in the lateral wings of the anterior pituitary gland.
The growth hormone helps in increasing height during childhood, raises calcium retention levels, strengthens and improves bone mineralization. It also increases the muscle mass through sarcomere hypertrophy, increases protein synthesis, promotes lipolysis, enhances the growth of all internal organs excluding the brain. The hormone has a key role to play in homeostasis, it helps to reduce glucose uptake by the liver.
Growth hormone (GH) treatment has only been used to help children with severe growth hormone deficiency (GHD). Nevertheless, today, with an excess of recombinant human GH (rhGH), it is also used to treat a wide range of other conditions. RhGH may be used to treat short-term GH deficiency (GHD), insufficiency, and other disorders leading to poor growth. At present, it is also used in patients with chronic renal failure (CRF), Prader Willi syndrome (PWS), Turner syndrome (TS), small gestational age (SGA) with no upward development of 2 years, idiopathic short stature (ISS) and some short-term dysmorphic syndromes. Through the growth hormone therapy, many children can attain adult heights better than expected- on the basis of their growth pattern of pretreatment.
Based on Application, the market is segmented into Small for Gestational Age, Prader-Willi Syndrome, Idiopathic Short Stature, Turner Syndrome, Growth Hormone Deficiency and Other Applications. Based on the type of Growth Hormone Deficiency, the application of Human Growth Hormone is studied across Pediatric Growth Hormone Deficiency and Adult Growth Hormone Deficiency. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy, Specialty Pharmacy and Online Pharmacy. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck Group, Teva Pharmaceuticals Industries Ltd., Ipsen Pharma Biotech SAS, Novartis AG (Sandoz International GmbH), Pfizer, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Ferring Holdings SA, Novo Nordisk A/S, Eli Lilly and Company, and Anhui Anke Biotechnology Group Co., Ltd.
- Small for Gestational Age
- Prader-Willi Syndrome
- Idiopathic Short Stature
- Turner Syndrome
- Growth Hormone Deficiency and
- ·Pediatric Growth Hormone Deficiency
- ·Adult Growth Hormone Deficiency
- Other Applications
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Specialty Pharmacy
- Online Pharmacy
- North America
- ·Rest of North America
- ·Rest of Europe
- Asia Pacific
- ·South Korea
- ·Rest of Asia Pacific
- ·Saudi Arabia
- ·South Africa
- ·Rest of LAMEA
- Merck Group
- Teva Pharmaceuticals Industries Ltd.
- Ipsen Pharma Biotech SAS
- Novartis AG (Sandoz International GmbH)
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
- Ferring Holdings SA
- Novo Nordisk A/S
- Eli Lilly and Company
- Anhui Anke Biotechnology Group Co., Ltd.